Divestiture/carve-outMar 20, 2026Completed
🇺🇸 United States
BRBreathe Right and certain other brands (including Dimetapp and Anbesol)PCPrestige Consumer Healthcare Inc.
Consumer & Retail › Consumer Products
Enterprise value$1.04BEnterprise value
AnnouncedMar 20, 2026
ConsiderationCash
StructureOther
RegionNorth America
Cross-borderNo
Contingent paymentNo
Overview
Prestige Consumer Healthcare entered into an agreement to acquire the Breathe Right nasal strip brand and other brands such as Dimetapp and Anbesol from Foundation Consumer Healthcare for $1.045 billion, or about $900 million net of anticipated tax benefits.
Deal rationale
The acquisition adds an iconic, category-leading brand with strong margins and free cash flow, expanding Prestige into a new category and reinforcing its long-term organic growth.
AI-generated from the SEC filingCompletedConsumer & Retail › Consumer ProductsUnited StatesNorth America
Timeline
Valuation and terms
| Equity value | Undisclosed | |
|---|---|---|
| Enterprise value | $1.04B | Headline figure |
| Consideration | Cash |
Advisors
Buy-side
CCiti
Sell-side
CGCanaccord Genuity
Parties
Target
BRBreathe Right and certain other brands (including Dimetapp and Anbesol)
- Headquarters
- United States
- Ticker
- —
Seller
FCFoundation Consumer Healthcare
- Headquarters
- —
- Ticker
- —